
    
      NGP 555 is a gamma-secretase modulator with a selective mechanism to reduce Abeta 42 while
      raising shorter Abeta forms such as Abeta 37 and 38.

      NGP 555 is being developed as a preventative disease modifying therapy for Alzheimer's
      disease.
    
  